| BCc1 nanomedicine (n = 33) | Placebo (n = 30) |
---|---|---|
Age, years | ||
 Mean (SD) | 59.8 ± 13 | 61.2 ± 12.93 |
Weight | ||
 Mean (SD) | 61.68 ± 12.24 | 55.62 ± 12.82 |
Gender (n) | ||
 Male–female | 23–10 | 20–10 |
Metastatic site (n) | ||
 Liver | 17 | 11 |
 Multiple site | 9 | 10 |
 Lung | 2 | 3 |
 Peritoneal carcinomatosis | 5 | 4 |
Stage 4 (n) | 33 | 30 |
 Site of involvement (n) | ||
  Cardia | 7 | 10 |
  Antrum | 6 | 5 |
  Fundus | 3 | 3 |
  Greater curvature | 3 | 4 |
  Lesser curvature | 4 | 3 |
  Diffuse | 4 | 5 |
Intervention + chemotherapy (n) | 14 | 19 |
Intervention + chemotherapy + radiotherapy (n) | 0 | 1 |